In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Iterum Therapeutics Plc (NASDAQ: ITRM) closed at $0.45 in the last session, down -4.13% from day before closing price of $0.47. In other words, the price has decreased by -$4.13 from its previous closing price. On the day, 0.52 million shares were traded. ITRM stock price reached its highest trading level at $0.49 during the session, while it also had its lowest trading level at $0.45.
Ratios:
We take a closer look at ITRM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.96 and its Current Ratio is at 2.13.
On March 15, 2021, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $2.50.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on June 02, 2020, whereas the target price for the stock was revised from $7 to $2.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’25 when Dunne Michael W. bought 6,000 shares for $0.37 per share. The transaction valued at 2,191 led to the insider holds 241,001 shares of the business.
Dunne Michael W. bought 15,000 shares of ITRM for $10,854 on Aug 08 ’25. The Director now owns 235,001 shares after completing the transaction at $0.72 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITRM now has a Market Capitalization of 21623020 and an Enterprise Value of 46487456. For the stock, the TTM Price-to-Sale (P/S) ratio is 60.90. Its current Enterprise Value per Revenue stands at 119.199 whereas that against EBITDA is -2.406.
Stock Price History:
The Beta on a monthly basis for ITRM is 2.84, which has changed by -0.74919784 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, ITRM has reached a high of $2.18, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is -22.31%, while the 200-Day Moving Average is calculated to be -48.60%.
Shares Statistics:
According to the various share statistics, ITRM traded on average about 943.33K shares per day over the past 3-months and 691360 shares per day over the past 10 days. A total of 52.79M shares are outstanding, with a floating share count of 52.37M. Insiders hold about 0.87% of the company’s shares, while institutions hold 2.52% stake in the company. Shares short for ITRM as of 1764288000 were 1644040 with a Short Ratio of 1.74, compared to 1761868800 on 1352384. Therefore, it implies a Short% of Shares Outstanding of 1644040 and a Short% of Float of 3.1400003.
Earnings Estimates
The performance of Iterum Therapeutics Plc (ITRM) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.59 and -$0.73 for the fiscal current year, implying an average EPS of -$0.66. EPS for the following year is -$0.31, with 2.0 analysts recommending between -$0.24 and -$0.38.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $1.4M. There is a high estimate of $1.4M for the next quarter, whereas the lowest estimate is $1.4M.
Based on 2 analysts’ estimates, the company’s revenue will be $9.38M in the next fiscal year. The high estimate is $10M and the low estimate is $8.75M.
